Abstract: The present invention provides mutant RSV F molecules, such as those that can be, or are stabilized, in a pre-fusion conformation by the introduction of one or more DT cross-links. The present invention also provides methods of making such mutant RSV F molecules, compositions comprising such mutant RSV F molecules, and methods of use of such mutant RSV F molecules, for example in vaccination methods, therapeutic methods, and antibody production methods.
Type:
Grant
Filed:
February 9, 2022
Date of Patent:
March 12, 2024
Inventors:
Christopher Marshall, Mark Yondola, Roberto Mariani, Aaron Zomback, Sonal Gidwani
Abstract: A reversible seat assembly for use in an automotive vehicle has an inboard seat riser, an outboard seat riser, a seat cushion, a seat back, a plurality of inboard reversing links, a plurality of outboard reversing links, a plurality of inboard strikers coupled to the inboard seat riser and a plurality of outboard strikers coupled to the outboard seat riser. The seat cushion is coupled to the inboard and outboard seat risers, and extends between a front end and a rear end. The seat back comprises an inboard latch bracket and an outboard latch bracket. The plurality of inboard reversing links extend between an upper end pivotally coupled to the inboard latch bracket and a lower end pivotally coupled to the inboard seat riser, and the plurality of outboard reversing links extend between an upper end pivotally coupled to the outboard latch bracket and a lower end pivotally coupled to the outboard seat riser.
Type:
Grant
Filed:
March 18, 2019
Date of Patent:
March 5, 2024
Assignee:
Magna Seating Inc.
Inventors:
Louis Vetere, II, Michael D Nacy, Kai Zhao, Detjon Marini, Cheikh Dioum
Abstract: A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.
Type:
Grant
Filed:
July 9, 2022
Date of Patent:
March 5, 2024
Assignee:
Altimmune UK Limited
Inventors:
Bertrand Victor Gilbert Georges, Carlton Bradley Brown
Abstract: Genetically modified rodents such as mice and rats, and methods and compositions for making and using the same, are provided. The rodents comprise a humanization of at least one endogenous rodent Tmprss gene, such as an endogenous rodent Tmprss2, Tmprss4, or Tmprss11d gene.
Type:
Grant
Filed:
November 17, 2020
Date of Patent:
February 27, 2024
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Lisa Purcell, Alexander O. Mujica, Yajun Tang
Inventors:
Niklas Gustafsson, Maria Hanshella R. Magno, Andrew Richard Phinney, Klaus Rosburg, Koby Hebborn Trout, Marc Thomas Wiescinski, Marcos Orlando Ortiz, Joseph Thomas Gar Jun Smith, Matthew Stewart Twiss, Daniel K. Patu